Citations 2
A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.
Riedel, Richard F. , Lu, Yao , Attia, Steven , Ganjoo, Kristen N. , Livingston, Michael B. , Ward, John Harris, Rushing, Daniel A., Okuno, Scott H. , Keedy, Vicki L. , Ryan, Christopher W. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Ballman, Karla V. , Loggers, Elizabeth T , Chow, Warren , Wright, Jennifer , Reed, Damon R. , Liebner, David A. , Mascarenhas, Leo , Davis, Lara E. , Reinke, Denise K.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11505-11505
Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.
Rixe, Olivier , Ward, John Harris, Drabick, Joseph J. , Shaheen, Montaser , Vahanian, Nicholas N., Link, Charles J., Zakharia, Yousef , Milhem, Mohammed , Munn, David H. , Kennedy, Eugene Paul , McWilliams, Robert R.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 9512-9512